Dogwood Therapeutics, INC. (DWTX) — DEF 14A Filings
All DEF 14A filings from Dogwood Therapeutics, INC.. Browse 4 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (4)
-
DWTX Seeks Shareholder Nod for Preferred Stock Conversion, Equity Plan
— Oct 20, 2025 Risk: medium
Dogwood Therapeutics, Inc. (DWTX) is holding a Special Meeting on November 21, 2025, to seek stockholder approval for several key proposals related to its recen -
Dogwood Therapeutics Files Definitive Proxy Statement
— Apr 30, 2025 Risk: low
Dogwood Therapeutics, Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting on June 18, 2025. The company, formerly known as Virio -
Virios Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders
— Apr 25, 2024 Risk:
Virios Therapeutics, Inc. (DWTX) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The 2024 Annual Meeting of Stockholders for Virios Therapeuti -
Virios Therapeutics seeks shareholder approval for a reverse stock split to fund Phase 2 development of IMC-2 for Long-COVID.
— Feb 2, 2024 Risk:
Virios Therapeutics, Inc. (DWTX) filed a Proxy Statement (DEF 14A) with the SEC on February 2, 2024. Virios Therapeutics plans to advance its development candid
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX